Trump Speeds FDA Reviews for Psychedelics

April 20, 2026·about 3 hours ago·via Pharmaceutical Executive

President Trump signs an executive order directing the FDA to accelerate reviews for psychedelic drugs, cutting through bureaucratic red tape that has stifled innovation for too long. This bold move prioritizes American patients and researchers over globalist regulations and big-government delays, potentially unlocking treatments for mental health crises ravaged by opioid epidemics and lockdown fallout. Read more about this...

Related Coverage

WebsiteKash Patel says 2020 election fraud arrests are 'coming soon' — The Blaze

WebsiteIran's Last Chance To Avoid Finding Out What's Behind Door Number B-2 — Hot Air

SubstackTrump’s Not Paying Attention to His Own War — The Bulwark

WebsiteFTC orders pest-control company to cease employees' noncompete agreements — Washington Times

WebsiteEliminating Fraud At The Forefront of President’s Agenda — The Gateway Pundit

WebsiteTrump tells The Post he ‘won’t be rushed’ to end Iran war, lashes out at pols urging him to settle: ‘They are helping the other side’ — New York Post

WebsiteTriggered 'Journalists' Plan to Give Trump a 1st Amendment Lecture at the WHCD (Per This Whiny Petition) — Twitchy